Stemline Therapeutics (STML) Downgraded by BidaskClub

BidaskClub downgraded shares of Stemline Therapeutics (NASDAQ:STML) from a hold rating to a sell rating in a report issued on Friday.

Several other equities research analysts also recently issued reports on the company. Cowen reiterated a buy rating on shares of Stemline Therapeutics in a report on Tuesday, October 31st. HC Wainwright upped their price objective on Stemline Therapeutics from $34.00 to $38.00 and gave the company a buy rating in a research note on Wednesday, November 1st. Three research analysts have rated the stock with a sell rating and five have issued a buy rating to the company. The stock has a consensus rating of Hold and an average price target of $33.75.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at $13.90 on Friday. Stemline Therapeutics has a 1-year low of $5.50 and a 1-year high of $16.00. The stock has a market capitalization of $357.93, a price-to-earnings ratio of -5.41 and a beta of -0.02.

In other Stemline Therapeutics news, COO Kenneth Hoberman sold 11,943 shares of the company’s stock in a transaction on Friday, December 15th. The stock was sold at an average price of $14.18, for a total value of $169,351.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 16.70% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Empire Life Investments Inc. purchased a new position in shares of Stemline Therapeutics during the 3rd quarter valued at $373,000. Cowen Inc. purchased a new position in shares of Stemline Therapeutics during the 3rd quarter valued at $420,000. Lyon Street Capital LLC lifted its position in shares of Stemline Therapeutics by 331.1% during the 3rd quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock valued at $6,010,000 after buying an additional 415,867 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Stemline Therapeutics by 82.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 219,252 shares of the biopharmaceutical company’s stock valued at $2,434,000 after buying an additional 98,775 shares during the last quarter. Finally, C WorldWide Group Holding A S purchased a new position in shares of Stemline Therapeutics during the 3rd quarter valued at $1,776,000. 50.24% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Stemline Therapeutics (STML) Downgraded by BidaskClub” was originally posted by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.com-unik.info/2017/12/25/stemline-therapeutics-stml-downgraded-by-bidaskclub.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

What are top analysts saying about Stemline Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Stemline Therapeutics and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit